HRMY — Harmony Biosciences Holdings Income Statement
0.000.00%
- $1.82bn
- $1.64bn
- $582.02m
- 86
- 71
- 63
- 85
Annual income statement for Harmony Biosciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6 | 160 | 305 | 438 | 582 |
Cost of Revenue | |||||
Gross Profit | 4.42 | 132 | 250 | 354 | 461 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 152 | 165 | 244 | 318 | 400 |
Operating Profit | -146 | -5.65 | 61.4 | 120 | 182 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -152 | -36.9 | 37.4 | 105 | 173 |
Provision for Income Taxes | |||||
Net Income After Taxes | -152 | -36.9 | 34.6 | 181 | 129 |
Net Income Before Extraordinary Items | |||||
Net Income | -152 | -36.9 | 34.6 | 181 | 129 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -187 | -63.8 | 34.6 | 181 | 129 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.93 | -0.724 | 0.993 | 2.97 | 2.25 |
Dividends per Share |